MOBILion Systems

Executive Summary

MOBILion Systems is a U.S.-based biotechnology company pioneering next-generation separation science through its high-resolution ion mobility mass spectrometry (HRIM-MS) platform. The technology enables deeper, faster, and more accurate characterization of complex molecules such as lipids, peptides, and glycans, addressing critical limitations of conventional mass spectrometry. Founded in 2016, the company has developed proprietary instruments that separate molecules based on size, shape, and charge, offering unprecedented resolution and throughput. This capability is vital for therapeutic development, diagnostics, and environmental testing, where precise molecular identification is essential. MOBILion’s platform has the potential to accelerate drug discovery, enhance biomarker identification, and improve diagnostic accuracy. The company is positioned for growth as demand for advanced analytical tools increases in the biopharma and clinical diagnostics markets. With a strong intellectual property portfolio and a clear focus on commercialization, MOBILion is attracting interest from pharmaceutical partners and investors. However, as a private firm, its progress is not publicly disclosed, and the path to widespread adoption depends on successful product launches and regulatory clearances. If the technology achieves validation in key applications, MOBILion could become a leading provider of high-resolution mass spectrometry solutions.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation HRIM-MS instrument (e.g., MOBIE 2.0)70% success
• Q3 2026Strategic partnership with a major pharmaceutical company for drug discovery60% success
• Q2 2027FDA clearance of platform for clinical diagnostic use (e.g., lipid profiling)40% success